Esteban Mena Porras

Dr. Esteban Mena Porras

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
EPEsteban Mena Porras
Esteban Mena Porras
ACAnnaby Contreras-Aleman
Annaby Contreras-Aleman
MHMaría Francinie Guevara Hidalgo
María Francinie Guevara Hidalgo
EAEsteban Damián Avendaño-Soto
Esteban Damián Avendaño-Soto
DMDiego Batista Menezes
Diego Batista Menezes
Daniel Chavarria-BolanosDaniel Chavarria-Bolanos
Daniel Chavarria-Bolanos
Objectives: This study aimed to synthesize polylactic acid (PLA) nanofibrillar scaffolds loaded with ibuprofen (IBU) using electrospinning (ES) and air-jet spinning (AJS). The scaffolds were evaluated for their physicochemical properties, drug release profiles, and biocompatibility to assess their potential for local analgesic applications. Methods: Solutions of 10% (w/v) PLA combined with IBU at concentrations of 10%, 20%, and 30% were processed into nanofibrillar membranes using ES and AJS. The scaffolds were characterized using scanning electron microscopy (SEM), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), and Fourier-transformed infrared (FT-IR) spectroscopy. The drug release profile was assessed by ultraviolet-visible spectrophotometry (UV-Vis), and cell adhesion and viability were evaluated using fibroblast culture assays. Statistical analyses included qualitative analyses, t-tests, and Likelihood ratio tests. Results: SEM revealed randomly arranged nanofibers forming reticulated meshes, with more uniform dimensions observed in the AJS group. TGA and DSC analyses confirmed the thermodynamic stability of the scaffolds and enthalpy changes consistent with IBU incorporation, which FT-IR and UV-Vis validated. Drug release was sustained over 384 h, showing no significant differences between ES and AJS scaffolds (p > 0.05). Cytotoxicity and cell viability assays confirmed scaffold biocompatibility, with cellular responses proportional to drug concentration but within safe limits. Conclusions: PLA-IBU nanofibrillar scaffolds were successfully synthesized using ES and AJS. Both methods yielded biocompatible systems with stable properties and controlled drug release. Further, in vivo studies are necessary to confirm their clinical potential.

30 April 2025 in Odovtos - International Journal of Dental Sciences
Verified
Journal Article
Open access
PDF file
CMClaudina Marcín-Montero
Claudina Marcín-Montero
VMVictor Martinez-Aguilar
Victor Martinez-Aguilar
RCRubén Castillo-Bolio
Rubén Castillo-Bolio
EPEsteban Mena Porras
Esteban Mena Porras
Amaury Pozos-GuillénAmaury Pozos-Guillén
Amaury Pozos-Guillén
Daniel Chavarria-BolanosDaniel Chavarria-Bolanos
Daniel Chavarria-Bolanos
Pre-prosthetic surgical procedures such as clinical crown lengthening (CLS), can cause pain, discomfort, and postoperative inflammation; causing the need of the prescription of medications such as analgesic, anti-inflammatories and in certain cases systemic antibiotics. However, prolonged and indiscriminate use of these medications often leads to adverse effects on general health. Thus, the ideal to treat locally pain and inflammation, and to prevent local infection is promising. The objective of this preliminary study was to evaluate the controlled use of a local chlorhexidine gel (CHXg) immediately place after pre-prosthetic periodontal surgery to manage postoperative pain using a customized whitening trays. A randomized controlled double-blind parallel-group clinical pilot trial was conducted. A sample of 10 patients aged 18 to 60 years, requiring a crown lengthening procedure was selected. Two groups (Group A: 0.2% CHXg vs Group B: placebo gel). Pain scores were evaluated by using a visual analog scale (VAS), and side effects and poswas 3.32 for Group A and 4.85 for Group B (p=0.05), with results showing no statistically significant difference. Few studies have assessed the effect and influence of 0.2% CHX gel on postoperative pain control. Some reports suggest that intra-alveolar use of CHX gel is more effective than administering 10 mg of ketorolac alone. In this study, there were no statistically significant differences, indicating that the use of 0.2% CHX gel applied after pre-prosthetic surgery may not significantly reduce postoperative pain.